Is KRAS (G12C) inhibitor monotherapy for non-small cell lung cancer possible? A review of current literature

KRAS mutations play an essential role in developing non-small cell lung cancer (NSCLC). Recently, the development of inhibitors for KRAS (G12C) has increased. The Food and Drug Administration has approved Sotorasib (AMG-510) and Adagrasib (MRTX-863) for the subsequent treatment of non-small cell lung cancer. However, with the spread of clinical application, the problem of the poor effect of single-agent use has been paid attention to more and more researchers. Most inhibitors have an objective response rate of less than 50%, and monotherapy does not further prolong overall survival in patients with advanced disease of NSCLC. Therefore, the search for sensitisation and resistance targets of KRAS (G12C) targeted drugs have been studied, and the corresponding regimens based on KRAS (G12C) targeted drugs in combination with other drugs have also begun to enter the clinical trial stage. This review will summarise the problems of single-agent use and the potential development of combinative schemes with KRAS (G12C) inhibitors and other drugs.